Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2022-08-25 Capital/Financing Update
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 5 to a Form S-1 Registration Statement filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of units consisting of common stock and warrants. The document includes a preliminary prospectus with detailed offering information, risk factors, use of proceeds, management discussion and analysis, business description, management, executive compensation, principal stockholders, underwriting, and legal matters. This type of filing is a capital raising document related to the company's financing activities and public offering of securities. It is not an annual report, earnings release, or other financial report but a registration statement for securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering and underwriting information, consistent with a capital raising filing.
2022-08-25 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Shuttle Pharmaceuticals Holdings, Inc. to the SEC Division of Corporation Finance, responding to comments on Amendment No. 3 to a Registration Statement on Form S-1. It discusses details about a private placement offering, compliance with Rule 506(b), and updates to disclosures in the Registration Statement. The document is a correspondence related to a registration statement filing, not the registration statement itself or a financial report. It is a regulatory communication addressing SEC comments on a securities offering filing. Therefore, it fits best under Regulatory Filings (RNS), as it is a regulatory submission and response rather than a financial report or announcement of a report.
2022-08-24 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 4 filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of units consisting of common stock and warrants. The document includes a preliminary prospectus with detailed offering information, risk factors, use of proceeds, management discussion, and other disclosures typical of an S-1 filing. This type of filing is related to capital raising and financing activities, specifically the registration of securities for public offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document is not an annual report, earnings release, or any other report type but a registration statement for securities offering.
2022-08-24 English
Regulatory Filings 2022
Regulatory Filings
2022-08-23 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A Registration Statement Amendment No. 3 filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It is a registration statement under the Securities Act of 1933 for a public offering of securities, including common stock and warrants. The document includes a preliminary prospectus with detailed offering terms, risk factors, use of proceeds, management discussion and analysis, business description, executive compensation, and other related sections typical of an IPO registration statement. This is not an annual report, earnings release, or any other financial report but a capital raising filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement and prospectus, not just an announcement or certification. Hence, the classification is CAP with high confidence.
2022-08-19 English
Regulatory Filings 2022
Regulatory Filings
2022-08-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.